Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The reality of Type 2 diabetes treatment today
Autore:
Morris, AD;
Indirizzi:
Univ Dundee, Ninewells Hosp & Med Sch, Dept Med, Dundee DD1 9SY, Scotland Univ Dundee Dundee Scotland DD1 9SY , Dept Med, Dundee DD1 9SY, Scotland
Titolo Testata:
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
, , anno: 2001, supplemento:, 121
pagine: 32 - 35
SICI:
1368-5031(200109):<32:TROT2D>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
MELLITUS; INSULIN; PREVENTION; DIET;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
16
Recensione:
Indirizzi per estratti:
Indirizzo: Morris, AD Univ Dundee, Ninewells Hosp & Med Sch, Dept Med, Dundee DD1 9SY, Scotland Univ Dundee Dundee Scotland DD1 9SY Dundee DD1 9SY, Scotland
Citazione:
A.D. Morris, "The reality of Type 2 diabetes treatment today", INT J CL PR, 2001, pp. 32-35

Abstract

The 5-year targets set by the St Vincent Declaration for cardiovascular events in Type 2 diabetes have still not been met, despite efforts to spread the word about the importance of treating cardiovascular risk factors in this population. Perhaps the advent of the thiazolidinediones will allow us to address a fundamental problem in Type 2 diabetes - insulin resistance-andthereby positively affect the raft of risk factors associated with the insulin resistance syndrome. However, adding a new drug to the list of medications taken by many patients with Type 2 diabetes may bring problems of compliance. As the prevalence of Type 2 diabetes increases with age so does that of concomitant diseases. Thus, a typical patient might be taking several tablets for these conditions as well as several for their diabetes and medications to address cardiovascular risk factors/disease too. These elderly patients may also be confused and/or have difficulty in opening the bottles and packets. Poor compliance is perhaps inevitable. Therefore, we should atleast try to use agents that need only once daily dosing whenever possible. Fortunately, pioglitazone is such an agent and has the added benefit of being a cost-effective way of reducing HbA(1c).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/07/20 alle ore 12:16:35